N-(4,6-DIMETHOXYPYRIMIDIN-2-YLCARBAMOYL)-3-((2,2,3,3,4,4,4-HEPTAFLUOROBUTOXY)METHYL)THIOPHENE-2-SULFONAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BYZAFWRBXQNZFV-UHFFFAOYSA-N
Smiles	COc1cc(OC)nc(NC(=O)NS(=O)(=O)c2sccc2COCC(F)(F)C(F)(F)C(F)(F)F)n1
InChI	InChI=1S/C16H15F7N4O6S2/c1-31-9-5-10(32-2)25-12(24-9)26-13(28)27-35(29,30)11-8(3-4-34-11)6-33-7-14(17,18)15(19,20)16(21,22)23/h3-5H,6-7H2,1-2H3,(H2,24,25,26,27,28)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H15F7N4O6S2
Molecular Weight	556.43
AlogP	3.47
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	11.0
Polar Surface Area	165.35
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	35.0

Assay Description	Organism	Bioactivity
Toxicity in two leaf stage of Oryza sativa var. Nihonbare (rice) assessed as dose required to selectivity to Oryza sativa	Oryza sativa	0.625 g/acre
Herbicidal activity against Sagittaria pygmaea assessed as dose required to cause sufficient herbicidal activity after 5 to 7 days	Sagittaria pygmaea	10.0 g/acre
Herbicidal activity against Echinochloa oryzicola assessed as dose required to cause sufficient herbicidal activity	Echinochloa oryzicola	10.0 g/acre
Herbicidal activity against Schoenoplectiella juncoides assessed as dose required to cause sufficient herbicidal activity after 5 to 7 days	Schoenoplectiella juncoides	20.0 g/acre

Cross References

Resources	Reference
ChEMBL	CHEMBL2286338
PubChem	76320080

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).